• EVOCAL Health

EVOCAL HEALTH selected for the German Accelerator

EVOCAL Health part of the German Accelerator Kickstart International


Hamburg/Berlin/Munich (Germany), July 1, 2021: EVOCAL Health, a biopharmaceutical digital health company unlocking the human voice as a biomarker for AI-based detection and treatment of diseases (so-called vocal biomarkers), today announced to be selected for the German Accelerator Kickstart International Program.


The German Accelerator is one of the most prestigious accelerators for upstarting companies in Germany. The program is funded by German Federal Ministry for Economic Affairs and Energy (Bundesministerium für Wirtschaft und Energie) and empowers high-potential German companies to scale globally and enter on a fast-paced learning journey in some of the world’s leading innovation hubs.


The program is dedicated to addressing the specific needs and challenges of German companies on their internationalization roadmap to the U.S. and Asia, but the program goes much further: A successful internationalization strategy is interconnected with many factors and requires a deep understanding of foreign markets, business models, and fundraising strategy. The program highlights many of the interconnected aspects of internationalization and provides a solid basis for decision making as well as access to a valuable mentor network across the U.S. and Asia.


In an interview with German Accelerator, EVOCAL Health Co-Founder & CEO/COO Philip Mertes explains why internationalization is especially complex in healthcare: “Especially for Life Sciences companies with significantly longer and more complex product commercialization cycles, creating a viable roadmap for international expansion that includes clinical, regulatory, and reimbursement strategy in your target markets is time-consuming and requires a lot of work to get the basics right.”